CN106715467B - 涉及经工程改造的cd16的多肽、细胞和方法 - Google Patents

涉及经工程改造的cd16的多肽、细胞和方法 Download PDF

Info

Publication number
CN106715467B
CN106715467B CN201580028172.2A CN201580028172A CN106715467B CN 106715467 B CN106715467 B CN 106715467B CN 201580028172 A CN201580028172 A CN 201580028172A CN 106715467 B CN106715467 B CN 106715467B
Authority
CN
China
Prior art keywords
cells
cell
cd16a
therapeutic
bike
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580028172.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN106715467A (zh
Inventor
B.K.沃尔彻克
D.S.考夫曼
吴建明
Y.京
倪振亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Priority to CN202110757729.3A priority Critical patent/CN113699159A/zh
Publication of CN106715467A publication Critical patent/CN106715467A/zh
Application granted granted Critical
Publication of CN106715467B publication Critical patent/CN106715467B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201580028172.2A 2014-03-28 2015-03-27 涉及经工程改造的cd16的多肽、细胞和方法 Active CN106715467B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110757729.3A CN113699159A (zh) 2014-03-28 2015-03-27 涉及经工程改造的cd16的多肽、细胞和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971996P 2014-03-28 2014-03-28
US61/971996 2014-03-28
PCT/US2015/022998 WO2015148926A1 (en) 2014-03-28 2015-03-27 Polypeptides, cells, and methods involving engineered cd16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110757729.3A Division CN113699159A (zh) 2014-03-28 2015-03-27 涉及经工程改造的cd16的多肽、细胞和方法

Publications (2)

Publication Number Publication Date
CN106715467A CN106715467A (zh) 2017-05-24
CN106715467B true CN106715467B (zh) 2021-07-27

Family

ID=52829414

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580028172.2A Active CN106715467B (zh) 2014-03-28 2015-03-27 涉及经工程改造的cd16的多肽、细胞和方法
CN202110757729.3A Pending CN113699159A (zh) 2014-03-28 2015-03-27 涉及经工程改造的cd16的多肽、细胞和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110757729.3A Pending CN113699159A (zh) 2014-03-28 2015-03-27 涉及经工程改造的cd16的多肽、细胞和方法

Country Status (9)

Country Link
US (4) US10464989B2 (enExample)
EP (2) EP4227318A1 (enExample)
JP (4) JP6795399B2 (enExample)
CN (2) CN106715467B (enExample)
AU (3) AU2015235852B2 (enExample)
CA (1) CA2944199C (enExample)
ES (1) ES2941679T3 (enExample)
PT (1) PT3122769T (enExample)
WO (1) WO2015148926A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3122769T (pt) * 2014-03-28 2023-04-24 Univ Minnesota Polipéptidos, células e métodos que envolvem cd16 manipulado
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
CN108368520B (zh) * 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
JP2018537536A (ja) * 2015-12-09 2018-12-20 ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
US10767183B2 (en) 2016-03-09 2020-09-08 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
WO2018126074A1 (en) * 2016-12-30 2018-07-05 Celularity, Inc. Genetically modified natural killer cells
JP2021500923A (ja) * 2017-10-26 2021-01-14 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 組換え免疫細胞、作製方法、および使用方法
KR20250048610A (ko) * 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
US20210024959A1 (en) * 2018-03-29 2021-01-28 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
WO2020097049A1 (en) 2018-11-05 2020-05-14 American Gene Technologies International Inc. Vector system for expressing regulatory rna
AU2019392265A1 (en) 2018-12-02 2021-06-03 Fate Therapeutics, Inc. Immunotherapies using enhanced iPSC derived effector cells
BR112022000641A2 (pt) 2019-07-17 2022-03-29 Fate Therapeutics Inc Modificação genética de célula efetora imune e uso da mesma
WO2021022229A1 (en) * 2019-07-31 2021-02-04 Celularity Inc. Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en) * 2019-12-05 2021-06-10 Celularity Inc. Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
US12275955B2 (en) 2020-06-19 2025-04-15 Fate Therapeutics, Inc. Combining iPSC derived effector cell types for immunotherapy use
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022159775A1 (en) * 2021-01-21 2022-07-28 American Gene Technologies International, Inc. Engineered nk cells and methods of treating cancer
KR102894135B1 (ko) * 2021-09-29 2025-12-04 카오티에스 주식회사 신규한 재조합 Fc 수용체 및 이를 포함하는 세포
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
CN114774469B (zh) * 2022-06-22 2022-11-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
WO2024067682A1 (zh) * 2022-09-29 2024-04-04 上海先博生物科技有限公司 工程改造的免疫效应细胞及其组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852976A (zh) * 2003-07-26 2006-10-25 特鲁比昂药品公司 结合构建体及其使用方法
WO2010040091A1 (en) * 2008-10-03 2010-04-08 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Novel dna nanostructures that promote cell-cell interaction and use thereof
EP1734119A3 (en) * 1995-05-03 2012-12-05 Merck Serono SA CD16-II variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121788A (en) * 1871-12-12 Improvement in match-boxes
CA2550998A1 (en) 2003-12-22 2005-07-14 Chiron Corporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
EP2921500B1 (en) * 2004-07-10 2023-08-30 The Institute for Cancer Research Genetically modified human natural killer cell lines
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
JP2009500458A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド ヒト化抗ｃｄ１６ａ抗体を用いる自己免疫疾患の治療方法
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
PT3122769T (pt) 2014-03-28 2023-04-24 Univ Minnesota Polipéptidos, células e métodos que envolvem cd16 manipulado

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734119A3 (en) * 1995-05-03 2012-12-05 Merck Serono SA CD16-II variants
CN1852976A (zh) * 2003-07-26 2006-10-25 特鲁比昂药品公司 结合构建体及其使用方法
WO2010040091A1 (en) * 2008-10-03 2010-04-08 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Novel dna nanostructures that promote cell-cell interaction and use thereof

Also Published As

Publication number Publication date
EP3122769B1 (en) 2023-02-22
US20170174743A1 (en) 2017-06-22
JP6795399B2 (ja) 2020-12-02
JP2022121484A (ja) 2022-08-19
CN113699159A (zh) 2021-11-26
US20240417441A1 (en) 2024-12-19
AU2015235852B2 (en) 2019-08-15
WO2015148926A1 (en) 2015-10-01
JP2025004257A (ja) 2025-01-14
EP3122769A1 (en) 2017-02-01
JP7091423B2 (ja) 2022-06-27
ES2941679T3 (es) 2023-05-24
CA2944199A1 (en) 2015-10-01
AU2022204134B2 (en) 2024-11-28
US11370825B2 (en) 2022-06-28
US10464989B2 (en) 2019-11-05
AU2015235852A1 (en) 2016-10-20
AU2022204134A1 (en) 2022-06-30
JP2017511135A (ja) 2017-04-20
US20200017570A1 (en) 2020-01-16
AU2019250155A1 (en) 2019-10-31
AU2019250155B2 (en) 2022-03-17
WO2015148926A9 (en) 2016-11-10
EP4227318A1 (en) 2023-08-16
CN106715467A (zh) 2017-05-24
CA2944199C (en) 2023-08-15
JP7575426B2 (ja) 2024-10-29
US20210332103A1 (en) 2021-10-28
JP2021035390A (ja) 2021-03-04
PT3122769T (pt) 2023-04-24
US12098182B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
JP7575426B2 (ja) 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
EP4509186A2 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
JP2025011176A (ja) 組換え免疫細胞、作製方法、および使用方法
CN117886949A (zh) 结合触发的转录开关及其使用方法
US12345711B2 (en) Methods to determine antibody activity in tumor samples
CA3201621A1 (en) Genetically engineered cells and uses thereof
CN107523546A (zh) 一种高效稳定表达抗体的nk细胞及其用途
CN116981685A (zh) 基因工程化细胞及其用途
HK40064550A (en) Polypeptides, cells, and methods involving engineered cd16
HK40101335A (en) Polypeptides, cells, and methods involving engineered cd16
HK1237796A1 (en) Polypeptides, cells, and methods involving engineered cd16
HK1237796B (zh) 涉及经工程改造的cd16的多肽、细胞和方法
Meseck et al. A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer
HK40025672A (en) Recombinant immune cells, methods of making, and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237796

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant